NeuroTrax Science Team and Glen M. Doniger, PhD
What if a routine vaccine could do more than prevent infection and actually influence long-term brain health? New research suggests that common preventive care may play a role in reducing Alzheimer’s disease risk, offering a new way of thinking about cognitive decline.
A recent study published in Neurology adds to a growing body of evidence suggesting that common medical interventions may influence Alzheimer’s disease risk. Researchers found that older adults who received a high-dose influenza vaccine had a significantly lower risk of developing Alzheimer’s dementia compared to those receiving the standard dose [1].
In a large U.S. cohort study including nearly 200,000 individuals aged 65 and older, high-dose vaccination was associated with a lower cumulative risk of Alzheimer’s over the first two years following vaccination [2]. Some analyses suggest the reduction may be substantial, with estimates approaching 50–55% lower risk compared to standard-dose vaccination [3].
These findings are important because they reinforce a broader shift in how Alzheimer’s disease is understood. Traditionally viewed as a purely neurodegenerative condition, it is now increasingly linked to systemic factors such as inflammation and immune function. Vaccination may influence these pathways, potentially reducing neuroinflammatory processes that contribute to cognitive decline [2].
Equally important is the scale of the intervention. Influenza vaccination is already widely recommended, especially for older adults. Even modest reductions in Alzheimer’s risk could translate into meaningful public health impact given the growing prevalence of dementia worldwide [2].
However, these findings should be interpreted with caution. The study is observational, meaning that it cannot evaluate causation. Differences in healthcare access, lifestyle, or baseline health may contribute to the observed effects [1]. Still, the consistency of findings across research highlights the importance of immune-related pathways in Alzheimer’s risk.
While population-level findings are valuable, they raise an essential clinical question: how do we determine whether these risk-reducing factors are actually influencing cognitive function in individual patients? This is where objective cognitive measurement becomes critical.
NeuroTrax, a digital neuromarker, provides a standardized way to quantify cognitive function across key domains, including memory, executive function, attention, processing speed, and visual spatial ability. Unlike subjective reports or one-time screening tools, digital neurometrics allow clinicians to establish baseline cognitive function, detect subtle, domain-specific changes over time and track longitudinal cognitive trajectories.
In the context of emerging risk-modifying strategies like vaccination, this capability is essential. It allows clinicians to move beyond a population-level association and assess how interventions may influence cognitive outcomes in individual patients.
The Neurology study highlights an important shift toward prevention in Alzheimer’s research. But preventive steps without measurement obscures clinical impact.
Digital neuromarkers like NeuroTrax help bridge this gap by translating research findings into measurable patient outcomes. They enable clinicians to monitor whether a patient’s cognitive function remains stable, improves, or declines over time, providing a clearer picture of disease risk and progression.
As new preventive strategies emerge, combining population-level insights with individual-level cognitive tracking will be essential. Together, they offer a comprehensive approach to brain health that not only identifies risk but actively measures and manages its clinical impact.
References:
[1] Bukhbinder, A.S., Ling, Y., Jhin, L., He, E., Harris, K., Rodriguez, M., Thomas, J., Cruz, G., Phelps, K., Kim, Y., Chen, L., Jiang, X., and Schulz P.E. (2026). High-dose influenza vaccination and risk of Alzheimer’s disease. Neurology, 106(8):e214782. DOI: 10.1212/WNL.0000000000214782
[2] Risk of Alzheimer’s dementia significantly reduced after high-dose influenza vaccination compared to the standard dose, study finds. University of Texas Health Science Center at Houston (UTHealth) Press Release. Available at: https://www.uth.edu/news/story/risk-of-alzheimers-dementia-significantly-reduced-after-high-dose-influenza-vaccination-compared-to-the-standard-dose-study-finds
[3] Common vaccine slashes Alzheimer’s disease risk when dose increased. Fox News Health Article. Available at: https://www.foxnews.com/health/common-vaccine-slashes-alzheimers-disease-risk-when-dose-increased
